- First-quarter revenue growth of five percent, including four
percent organic growth
- Six percent organic revenue growth in termite and home
services
- Key investments in labor and staffing levels to drive
continued growth
- Acquisition by Rentokil remains on track for completion in
second half of 2022
Terminix Global Holdings, Inc. (NYSE: TMX), a leading provider
of essential termite and pest management services to residential
and commercial customers, today announced unaudited first-quarter
2022 results.
For the first quarter of 2022, the Company reported a
year-over-year revenue increase of five percent to $496 million.
Net income for the quarter decreased year-over-year by $8 million
to $19 million, or $0.15 per share. Adjusted EBITDA(1) for the
quarter decreased year-over-year by $4 million to $86 million, and
Adjusted Net Income(2) for the quarter increased by $3 million
year-over-year to $42 million, or $0.35 per share.
“We are encouraged by the positive momentum in our residential
business,” said Terminix CEO Brett Ponton. “Unit growth in termite
and strong price realization across all channels offset expected
inflationary pressures in fuel, labor and materials in the quarter.
Key investments in labor and staffing levels aided the first
quarter and will support growth in the coming quarters. Commercial
pest continues to improve, and with strong sales and improved
retention rates in the quarter, is poised for growth in the back
half of the year.”
“We continue to make progress on the Terminix Way initiative,”
continued Ponton. “We recently launched a pilot featuring enhanced
training and onboarding for route technician and improved home
inspection procedures that will enable a deeper relationship with
our customers. We continue to target completion of the Rentokil
merger by the end of the third quarter of 2022 and are making good
progress on integration planning across both the front-line and
back-office functions of our businesses.”
Consolidated Performance
Three Months Ended March
31,
$ millions
2022
2021
B/(W)
Revenue
$
496
$
471
$
25
YoY growth
5
%
Gross Margin
200
202
(2)
% of revenue
40.3
%
42.8
%
(2.5)
pts
SG&A
138
137
2
% of revenue
(27.9)
%
(29.0)
%
1.1
pts
Income before Income Taxes
21
37
(16)
% of revenue
4.2
%
7.8
%
(3.7)
pts
Net Income
19
27
(8)
% of revenue
3.8
%
5.7
%
(1.9)
pts
Adjusted Net Income(2)
42
39
3
% of revenue
8.5
%
8.4
%
0.1
pts
Adjusted EBITDA(1)
86
90
(4)
% of revenue
17.3
%
19.1
%
(1.8)
pts
Net Cash Provided from Operating
Activities from Continuing Operations
69
75
(6)
Free Cash Flow(3)
62
69
(7)
Reconciliations of Net Income to Adjusted Net Income and
Adjusted EBITDA, as well as a reconciliation of Net Cash Provided
from Operating Activities from Continuing Operations to Free Cash
Flow, are set forth below in this press release.
First-Quarter Performance
Revenue
Three Months Ended
March 31,
(In millions)
2022
2021
Growth
Organic
Acquired
Residential Pest Management
$
175
$
166
$
9
5
%
$
7
4
%
$
2
1
%
Commercial Pest Management
132
129
3
2
%
(1)
(1)
%
5
4
%
Termite and Home Services
171
162
10
6
%
9
6
%
—
—
%
Sales of Products and Other
18
15
3
18
%
3
18
%
—
—
%
Total revenue
$
496
$
471
$
25
5
%
$
18
4
%
$
6
1
%
In the first quarter of 2022, Terminix reported five percent
year-over-year revenue growth and four percent organic revenue
growth.(4)
Termite and Home Service growth was six percent, predominantly
all of which was organic growth. Termite completions increased 13
percent, driven by sales of our monthly pay tiered termite product.
Home services, which are managed as a component of our termite line
of business and include wildlife exclusion, crawl space
encapsulation and attic insulation, revenue growth was 19 percent,
primarily as a result of improved cross selling to existing
customers. Termite renewals decreased one percent, due to lower
volume, partially offset by improved price realization.
Residential pest management revenue growth was five percent,
reflecting organic revenue growth of four percent. Organic revenue
growth was driven by higher mosquito and bedbug sales volume,
improved trailing 12-month customer retention rates and improved
price realization. Residential pest management revenue also
increased one percent from acquisitions completed in the last 12
months.
Commercial pest management revenue growth was two percent. The
organic revenue decline of one percent was driven by a reduction in
one-time services including more than $1 million of disinfection
revenue in the prior year, partially offset by improved price
realization. International pest revenue was negatively impacted by
over $1 million of foreign currency. Excluding the impact of
foreign currency and disinfection revenue, commercial pest organic
growth would have been two percent. Commercial pest management
revenue also increased four percent from acquisitions completed in
the last 12 months.
Sales of products and other revenue growth was 18 percent due to
increased chemical demand as we lap the impacts of COVID-19 on
three months ended March 31, 2021 revenue.
Adjusted EBITDA
Adjusted EBITDA was $86 million for the first quarter, a
year-over-year decrease of $4 million. The impact on Adjusted
EBITDA from higher revenue was $13 million. Investments in labor
increased $6 million, primarily due to higher trainee and talent
acquisition expense as we increase our workforce for peak season.
Vehicle fuel increased $2 million year over year, driven by higher
fuel prices. Termite damage claims expenses increased $3 million
due to higher litigated claims counts in the Mobile Bay Area as
well as higher cost per Non-Litigated Claim due, in part, to
inflationary pressure on building materials and contractor costs.
Investments in Terminix Way increased $1 million as we continue to
roll-out enhanced onboarding, training and technology to our
technicians. Investments in staffing levels and training in both
sales and service in our call center increased $3 million. Travel
expenses increased $1 million due to the easing of COVID-19 travel
restrictions.
Liquidity and Free Cash Flow
The Company ended the first quarter with $170 million in
available cash and access to $348 million under its revolving
credit facility for total liquidity of $518 million. First-quarter
2022 free cash flow was $62 million, with a free cash flow to
Adjusted EBITDA conversion rate(5) of 73 percent. Given the
proposed acquisition by Rentokil, we do not intend to repurchase
shares of our common stock in the foreseeable future.
Update on Proposed Acquisition by Rentokil
As announced on March 15, 2022, the applicable waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has
expired, thereby completing the necessary antitrust process in the
US. A number of other conditions remain to be satisfied, including
obtaining approval by the Company’s and Rentokil’s shareholders,
and the registration of Rentokil’s American depository shares with
the U.S. Securities and Exchange Commission and their listing on
the New York Stock Exchange. With good progress being made on
satisfying the remaining conditions, both parties continue to be on
track to complete the transaction in the second half of 2022, with
a target completion date towards the end of the third quarter.
Full-Year 2022 Outlook
Due to the proposed acquisition by Rentokil, the Company does
not plan to provide its customary full-year 2022 revenue, Adjusted
EBITDA, organic growth or free cash flow conversion guidance.
First-Quarter 2022 Earnings Conference Call
The Company will hold a conference call to discuss its financial
and operating results at 8 a.m. central time (9 a.m. eastern time)
on Thursday, May 5, 2022.
The Company invites all interested parties to join Chief
Executive Officer Brett Ponton, Executive Vice President and Chief
Financial Officer Bob Riesbeck, and Vice President of Investor
Relations, FP&A and Treasurer Jesse Jenkins for an update on
the Company's operational performance and financial results for the
first-quarter ended 2022. Participants may join this conference
call by dialing 877.256.3294 (or international participants,
+1.303.223.0120). Additionally, the conference call will be
available via webcast. A slide presentation highlighting the
Company’s results will also be available. To participate via
webcast and view the presentation, visit the Company’s investor
relations home page at investors.terminix.com.
The call will be available for replay until June 4, 2022. To
access the replay of this call, please call 800.633.8284 and enter
reservation number 22017423 (international participants:
+1.402.977.9140, reservation number 22017423). The webcast will
also be available on the company’s investor relations home
page.
About Terminix
Terminix Global Holdings (NYSE: TMX) is a leading provider of
residential and commercial pest control. The Company provides pest
management services and protection against termites, mosquitoes,
rodents and other pests. Headquartered in Memphis, Tenn., with more
than 11,500 teammates and 2.9 million customers in 24 countries and
territories, the Company visits more than 50,000 homes and
businesses every day. To learn more about Terminix, visit
Terminix.com, or LinkedIn.com/company/terminix.
Additional Information About The Proposed Transaction And
Where To Find It
In connection with the proposed transaction between Rentokil and
Terminix, Rentokil will file with the U.S. Securities and Exchange
Commission (the “SEC”) a registration statement on Form F-4, which
will include a proxy statement of Terminix that also constitutes a
prospectus of Rentokil. Each of Rentokil and Terminix will also
file other relevant documents in connection with the proposed
transaction. The definitive proxy statement/prospectus will be sent
to the shareholders of Terminix. Rentokil will also file a
shareholder proxy circular in connection with the proposed
transaction with applicable securities regulators in the United
Kingdom and the shareholder proxy circular will be sent to
Rentokil’s shareholders. This press release is not a substitute for
any registration statement, proxy statement/prospectus or other
documents Rentokil and/or Terminix may file with the SEC in
connection with the proposed transaction. BEFORE MAKING ANY VOTING
OR INVESTMENT DECISIONS, INVESTORS, STOCKHOLDERS AND SHAREHOLDERS
OF TERMINIX AND RENTOKIL ARE URGED TO READ CAREFULLY AND IN THEIR
ENTIRETY THE PROXY STATEMENT/PROSPECTUS AND SHAREHOLDER PROXY
CIRCULAR, AS APPLICABLE, AND ANY OTHER RELEVANT DOCUMENTS THAT ARE
FILED OR WILL BE FILED WITH THE SEC OR APPLICABLE SECURITIES
REGULATORS IN THE UNITED KINGDOM, AS WELL AS ANY AMENDMENTS OR
SUPPLEMENTS TO THESE DOCUMENTS, IN CONNECTION WITH THE PROPOSED
TRANSACTION WHEN THEY BECOME AVAILABLE, AS THEY CONTAIN OR WILL
CONTAIN IMPORTANT INFORMATION ABOUT TERMINIX, RENTOKIL, THE
PROPOSED TRANSACTION AND RELATED MATTERS. The registration
statement and proxy statement/prospectus and other documents filed
by Rentokil and Terminix with the SEC, when filed, will be
available free of charge at the SEC’s website at www.sec.gov. In
addition, investors and shareholders will be able to obtain free
copies of the proxy statement/prospectus and other documents filed
with the SEC by Terminix online at investors.terminix.com, upon
written request delivered to Terminix at 150 Peabody Pl., Memphis,
TN 38103, USA, Attention: Corporate Secretary, or by calling
Terminix’s Corporate Secretary’s Office by telephone at +1
901-597-1400 or by email at deidre.richardson@terminix.com, and
will be able to obtain free copies of the registration statement,
proxy statement/prospectus, shareholder proxy circular and other
documents which will be filed with the SEC and applicable
securities regulators in the United Kingdom by Rentokil online at
https://www.rentokil-initial.com, upon written request delivered to
Rentokil at Compass House, Manor Royal, Crawley, West Sussex, RH10
9PY, England, Attention: Katharine Rycroft, or by calling Rentokil
by telephone at +44 (0) 7811 270734 or by email at
katharine.rycroft@rentokil-initial.com.
This press release is for informational purposes only and is not
intended to, and shall not, constitute an offer to sell or buy or
the solicitation of an offer to sell or buy any securities, nor
shall there be any sale of securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
appropriate registration or qualification under the securities laws
of any such jurisdiction. No offering of securities shall be made
except by means of a prospectus meeting the requirements of Section
10 of the U.S. Securities Act of 1933, as amended.
Participants in the Solicitation of Proxies
This press release is not a solicitation of proxies in
connection with the proposed transaction. However, under SEC rules,
Terminix, Rentokil, and certain of their respective directors,
executive officers and other members of the management and
employees may be deemed to be participants in the solicitation of
proxies in connection with the proposed transaction. Information
about Terminix’s directors and executive officers may be found on
its website at
corporate.terminix.com/responsibility/corporate-governance and in
its 2021 Annual Report on Form 10-K filed with the SEC on March 1,
2022, available at investors.terminix.com and www.sec.gov.
Information about Rentokil’s directors and executive officers may
be found on its website at https://www.rentokil-initial.com and in
its 2021 Annual Report filed with applicable securities regulators
in the United Kingdom on March 30, 2022, available on its website
at https://www.rentokil-initial.com. These documents can be
obtained free of charge from the sources indicated above.
Additional information regarding the interests of such potential
participants in the solicitation of proxies in connection with the
proposed transaction will be included in the proxy
statement/prospectus and shareholder proxy circular and other
relevant materials filed with the SEC and applicable securities
regulators in the United Kingdom when they become available.
Information Regarding Forward-Looking Statements
This press release contains forward-looking statements as that
term is defined in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can sometimes be identified by the use
of forward-looking terms such as “believes,” “expects,” “may,”
“will,” “shall,” “should,” “would,” “could,” “potential,” “seeks,”
“aims,” “projects,” “predicts,” “is optimistic,” “intends,”
“plans,” “estimates,” “targets,” “anticipates,” “continues” or
other comparable terms or negatives of these terms, but not all
forward-looking statements include such identifying words.
Forward-looking statements are based upon current plans, estimates
and expectations that are subject to risks, uncertainties and
assumptions. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those indicated or
anticipated by such forward-looking statements. We can give no
assurance that such plans, estimates or expectations will be
achieved and therefore, actual results may differ materially from
any plans, estimates or expectations in such forward-looking
statements. Important factors that could cause actual results to
differ materially from such plans, estimates or expectations
include: a condition to the closing of the proposed transaction may
not be satisfied; the occurrence of any event that can give rise to
termination of the proposed transaction; Rentokil is unable to
achieve the synergies and value creation contemplated by the
proposed transaction; Rentokil is unable to promptly and
effectively integrate Terminix’s businesses; management’s time and
attention is diverted on transaction related issues; disruption
from the proposed transaction makes it more difficult to maintain
business, contractual and operational relationships; the credit
ratings of Rentokil declines following the proposed transaction;
legal proceedings are instituted against Terminix or Rentokil;
Terminix or Rentokil is unable to retain or hire key personnel; the
announcement or the consummation of the proposed acquisition has a
negative effect on the market price of the capital stock of
Terminix or Rentokil or on Terminix’s or Rentokil’s operating
results; evolving legal, regulatory and tax regimes; changes in
economic, financial, political and regulatory conditions, in the
United Kingdom, the United States and elsewhere, and other factors
that contribute to uncertainty and volatility, natural and man-made
disasters, civil unrest, pandemics (e.g., the coronavirus
(COVID-19) pandemic (the “COVID-19 pandemic”)), geopolitical
uncertainty, and conditions that may result from legislative,
regulatory, trade and policy changes associated with the current or
subsequent U.S. or U.K. administration; the ability of Rentokil or
Terminix to successfully recover from a disaster or other business
continuity problem due to a hurricane, flood, earthquake, terrorist
attack, war, pandemic, security breach, cyber-attack, power loss,
telecommunications failure or other natural or man-made event,
including the ability to function remotely during long-term
disruptions such as the COVID-19 pandemic; the impact of public
health crises, such as pandemics (including the COVID-19 pandemic)
and epidemics and any related company or governmental policies and
actions to protect the health and safety of individuals or
governmental policies or actions to maintain the functioning of
national or global economies and markets, including any quarantine,
“shelter in place,” “stay at home,” workforce reduction, social
distancing, shut down or similar actions and policies; actions by
third parties, including government agencies; the risk that
disruptions from the proposed transaction will harm Rentokil’s or
Terminix’s business, including current plans and operations;
certain restrictions during the pendency of the acquisition that
may impact Rentokil’s or Terminix’s ability to pursue certain
business opportunities or strategic transactions; Rentokil’s or
Terminix’s ability to meet expectations regarding the accounting
and tax treatments of the proposed transaction; the risks and
uncertainties discussed in the “Risks and Uncertainties” section in
Rentokil’s reports available on the National Storage Mechanism at
morningstar.co.uk/uk/NSM and on its website at
https://www.rentokil-initial.com; and the risks and uncertainties
discussed in the “Risk Factors” and “Information Regarding
Forward-Looking Statements” sections in Terminix’s reports filed
with the SEC. These risks, as well as other risks associated with
the proposed transaction, will be more fully discussed in the proxy
statement/prospectus and shareholder proxy circular. While the list
of factors presented here is, and the list of factors to be
presented in proxy statement/prospectus and shareholder proxy
circular will be, considered representative, no such list should be
considered to be a complete statement of all potential risks and
uncertainties. Unlisted factors may present significant additional
obstacles to the realization of forward-looking statements. We
caution you not to place undue reliance on any of these
forward-looking statements as they are not guarantees of future
performance or outcomes and that actual performance and outcomes,
including, without limitation, our actual results of operations,
financial condition and liquidity, and the development of new
markets or market segments in which we operate, may differ
materially from those made in or suggested by the forward-looking
statements contained in this press release. Neither Rentokil nor
Terminix assumes any obligation to update or revise the information
contained herein, which speaks only as of the date hereof.
Non-GAAP Financial Measures
This press release contains certain non-GAAP financial measures.
Non-GAAP measures should not be considered as an alternative to
GAAP financial measures. Non-GAAP measures may not be calculated
like or comparable to similarly titled measures of other companies.
See non-GAAP reconciliations below in this press release for a
reconciliation of these measures to the most directly comparable
GAAP financial measures. Adjusted EBITDA, Adjusted Net Income,
Adjusted earnings per share, free cash flow, free cash flow to
Adjusted EBITDA conversion rate and organic revenue growth are not
measurements of the Company’s financial performance under GAAP and
should not be considered as an alternative to net income, net cash
provided by operating activities from continuing operations, net
earnings from discontinued operations or any other performance or
liquidity measures derived in accordance with GAAP. Management uses
these non-GAAP financial measures to facilitate operating
performance and liquidity comparisons, as applicable, from period
to period. We believe these non-GAAP financial measures are useful
for investors, analysts and other interested parties as they
facilitate company-to-company operating performance and liquidity
comparisons, as applicable, by excluding potential differences
caused by variations in capital structures, taxation, the age and
book depreciation of facilities and equipment, restructuring
initiatives and equity-based, long-term incentive plans.
_______________________________________________
(1) Adjusted EBITDA is defined as net income before:
depreciation and amortization expense; acquisition-related costs;
non-cash stock-based compensation expense; restructuring and other
charges; net earnings from discontinued operations; provision
(benefit) for income taxes; and interest expense. The Company’s
definition of Adjusted EBITDA may not be comparable to similarly
titled measures of other companies.
(2) Adjusted Net Income is defined as net income before:
amortization expense; acquisition-related costs; restructuring and
other charges; net earnings from discontinued operations; and the
tax impact of the aforementioned adjustments. The Company’s
definition of Adjusted Net Income may not be comparable to
similarly titled measures of other companies. Adjusted earnings per
share is calculated as Adjusted Net Income divided by the
weighted-average diluted common shares outstanding.
(3) Free cash flow is defined as net cash provided from
operating activities from continuing operations less property
additions.
(4) Organic revenue growth is defined as revenue excluding
revenue from acquired customers for 12 months following the
acquisition date.
(5) Free cash flow to Adjusted EBITDA conversion rate is defined
as free cash flow divided by Adjusted EBITDA.
TERMINIX GLOBAL HOLDINGS,
INC.
Consolidated Statements of
Operations and Comprehensive Income (Unaudited)
(In millions, except per share
data)
Three Months Ended
March 31,
2022
2021
Revenue
$
496
$
471
Cost of services rendered and products
sold
296
270
Selling and administrative expenses
138
137
Amortization expense
10
10
Acquisition-related costs
—
1
Restructuring and other charges
19
6
Interest expense
11
12
Interest and net investment income
1
(1
)
Income before Income Taxes
21
37
Provision for income taxes
3
11
Equity in earnings of joint ventures
1
—
Net Income
$
19
$
27
Other Comprehensive Income, Net of
Income Taxes:
Net unrealized gains on derivative
instruments
23
14
Foreign currency translation gain
5
8
Other Comprehensive Income, Net of
Income Taxes
28
22
Total Comprehensive Income
$
47
$
49
Weighted-average common shares outstanding
- Basic
121.4
131.4
Weighted-average common shares outstanding
- Diluted
121.6
131.9
Basic Earnings Per Share:
Net Income
0.15
0.20
Diluted Earnings Per Share:
Net Income
0.15
0.20
TERMINIX GLOBAL HOLDINGS,
INC.
Consolidated Statements of
Financial Position
(In millions, except share
data)
(Unaudited)
As of
As of
March 31,
December 31,
2022
2021
Assets:
Current Assets:
Cash and cash equivalents
$
170
$
116
Receivables, less allowances of $30 and
$32, respectively
195
206
Inventories
44
41
Prepaid expenses and other assets
164
151
Total Current Assets
573
514
Other Assets:
Property and equipment, net
192
196
Operating lease right-of-use assets
74
79
Goodwill
2,210
2,211
Intangible assets, primarily trade names,
service marks and trademarks, net
1,085
1,097
Restricted cash
89
89
Notes receivable
38
36
Long-term marketable securities
14
15
Deferred customer acquisition costs
94
98
Other assets
126
77
Total Assets
$
4,495
$
4,410
Liabilities and Stockholders'
Equity:
Current Liabilities:
Accounts payable
$
105
$
85
Accrued liabilities:
Payroll and related expenses
69
81
Self-insured claims and related
expenses
67
72
Accrued interest payable
3
7
Other
101
95
Deferred revenue
108
103
Current portion of lease liability
18
18
Current portion of long-term debt
77
50
Total Current Liabilities
547
511
Long-Term Debt
848
849
Other Long-Term Liabilities:
Deferred taxes
398
387
Other long-term obligations, primarily
self-insured claims
182
197
Long-term lease liability
92
92
Total Other Long-Term Liabilities
672
677
Stockholders' Equity:
Common stock $0.01 par value (authorized
2,000,000,000 shares with 149,330,124 shares issued and 121,493,685
outstanding at March 31, 2022 and 149,095,168 shares issued and
121,258,729 outstanding shares outstanding at December 31,
2021)
2
2
Additional paid-in capital
2,398
2,391
Retained Earnings
986
967
Accumulated other comprehensive income
(loss)
6
(22
)
Less common stock held in treasury, at
cost (27,836,439 shares at March 31, 2022 and 27,836,439 shares at
December 31, 2021)
(964
)
(964
)
Total Stockholders' Equity
2,428
2,375
Total Liabilities and Stockholders'
Equity
$
4,495
$
4,410
TERMINIX GLOBAL HOLDINGS,
INC.
Consolidated Statements of
Cash Flows (Unaudited)
(In millions)
Three Months Ended
March 31,
2022
2021
Cash and Cash Equivalents and
Restricted Cash at Beginning of Period
$
205
$
704
Cash Flows from Operating
Activities
Net Income
19
27
Equity in earnings of joint venture
(1
)
—
Depreciation expense
17
18
Amortization expense
10
10
Amortization of debt issuance costs
1
1
Amortization of lease right-of-use
assets
4
4
Payments on fumigation related matters
(3
)
—
Deferred income tax provision
2
5
Stock-based compensation expense
6
6
Restructuring and other charges
19
6
Payments for restructuring and other
charges
(10
)
(2
)
Acquisition-related costs
—
1
Payments for acquisition-related costs
—
(1
)
Other
(1
)
4
Change in working capital, net of
acquisitions:
Receivables
10
18
Inventories and other current assets
(10
)
(14
)
Accounts payable
20
5
Deferred revenue
5
7
Accrued liabilities
(14
)
(19
)
Accrued interest payable
(4
)
(4
)
Current income taxes
—
5
Net Cash Provided from Operating
Activities
69
75
Cash Flows from Investing
Activities
Property additions
(7
)
(6
)
Business acquisitions, net of cash
acquired
—
(22
)
Origination of notes receivable
(21
)
(15
)
Collections on notes receivable
18
17
Other investing
(31
)
—
Net Cash Used for Investing
Activities
(40
)
(26
)
Cash Flows from Financing
Activities
Borrowings of debt
80
—
Payments of debt
(65
)
(15
)
Repurchase of common stock
—
(169
)
Issuance of common stock and exercise of
stock options
1
4
Net Cash Used For Financing
Activities
16
(180
)
Cash Flows from Discontinued
Operations:
Cash provided from operating
activities
9
—
Net Cash Provided from Discontinued
Operations
9
—
Cash (Decrease) Increase During the
Period
54
(131
)
Cash and Cash Equivalents and
Restricted Cash at End of Period
$
258
$
573
The following table presents reconciliations of net income to
Adjusted Net Income:
Three Months Ended
March 31,
(In millions)
2022
2021
Net Income
$
19
$
27
Amortization expense
10
10
Acquisition-related costs
—
1
Restructuring and other charges
19
6
Tax impact of adjustments
(6
)
(4
)
Adjusted Net Income
$
42
$
39
Weighted-average diluted common shares
outstanding
121.6
131.9
Diluted earnings per share
$
0.15
$
0.20
Adjusted diluted earnings per share
$
0.35
$
0.30
The following table presents reconciliations of net cash
provided from operating activities from continuing operations to
free cash flow:
Three Months Ended
March 31,
(In millions)
2022
2021
Net Cash Provided from Operating
Activities from Continuing Operations
$
69
$
75
Property additions
(7
)
(6
)
Free Cash Flow
$
62
$
69
The following table presents reconciliations of net income to
Adjusted EBITDA.
Three Months Ended
March 31,
(In millions)
2022
2021
Net Income
$
19
$
27
Depreciation and amortization expense
28
28
Acquisition-related costs
—
1
Non-cash stock-based compensation
expense
6
6
Restructuring and other charges
19
6
Provision for income taxes
3
11
Interest expense
11
12
Adjusted EBITDA
$
86
$
90
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220504006313/en/
Investor Relations: Jesse Jenkins 901.597.8259
Jesse.Jenkins@terminix.com
Media: James Robinson 901.597.7521
James.Robinson@terminix.com
Terminix Global (NYSE:TMX)
Historical Stock Chart
From Nov 2024 to Dec 2024
Terminix Global (NYSE:TMX)
Historical Stock Chart
From Dec 2023 to Dec 2024